VIDEO: ‘Dramatic breakthroughs’ expected in neurotrophic keratitis

WAIKOLOA, Hawaii — In this expert perspective from Hawaiian Eye 2026, Francis W. Price Jr., MD, of Price Vision Group, discusses the latest in neurotrophic keratitis.
Price said pharmaceuticals are under study for neurotrophic keratitis, nonhealing epithelial defects and limbal stem cell deficiency. There are also new forms of amniotic membrane.
“We’re on the verge of some pretty exciting breakthroughs for these problems that have plagued some of our patients for a long time,” Price told Healio. “There are a lot of things in the pipeline. Keep your eyes open for

GLP-1 benefits must be balanced with pancreatitis risk

A recent Nature article on novel GLP-1 therapies underscores a truth few key opinion leaders in medicine like to focus on: Even the most clinically impactful pharmaceutical accomplishments carry serious and potentially deadly risks.
Potent GLP-1s — including semaglutide and tirzepatide — have become a cultural phenomenon, reshaping how millions around the world manage obesity, type 2 diabetes, fatty liver, sleep apnea, substance abuse disorders and established related cardiometabolic risks.
Yet, as regulators in the U.K. and Brazil have reported, there is mounting, if rare, evidence that these

VIDEO: Oncology education key to understanding growing data in breast cancer treatment

In this video, Paolo Tarantino, MD, PhD, an advanced fellow at Dana-Farber Cancer Institute, discusses the “need and appeal” for oncology education to contextualize “emerging and evolving data in breast oncology.”
He said meetings like Miami Breast Cancer Conference are “critical” for physicians to understand the growing treatment landscape for breast cancer subtypes.
“We need opportunity to engage, to discuss and to review, because things are moving so fast — so much faster than they've ever been moving,” Tarantino told Healio. “New

FDA grants fast track designation to nipocalimab for lupus

The FDA has granted fast track designation to the anti-FcRn agent nipocalimab for the treatment of adults with systemic lupus erythematosus, according to a manufacturer press release.
Nipocalimab (Imaavy, Johnson & Johnson) is an investigational immunoselective therapy that blocks FcRn and targets harmful IgG antibodies to reduce SLE disease activity, Johnson & Johnson said in the release.
“The fast-tracking of nipocalimab for the treatment of SLE represents an exciting potential advancement for our field,” Ashira D. Blazer, MD, assistant professor of medicine in the

Telehealth is great equalizer for postpartum care across racial lines, study finds

The postpartum period is one of the most challenging times for mothers of all backgrounds. In addition to providing 24-hour care for a newborn infant (and likely other members of the family) on limited, sporadic sleep, these individuals are recovering from childbirth. From c-sections and other surgical procedures to mastitis and UTI infections, new mothers face a myriad of health issues and complications in the weeks and months after delivery.

Analysis: In US health insurance market, consolidation of insurers is increasing premiums

The U.S. health insurance industry relies heavily on private markets, but these markets are highly concentrated and are growing more so over time. In a new analysis, researchers document concentration across commercial, Medicare Advantage, and Medicaid markets, examining how asymmetric information—particularly adverse selection—interacts with market power to shape premiums, plan designs, and consumer welfare. They conclude that consolidation of insurers boosts premiums, and they call for regulation and antitrust oversight.